20 Aug 2002
Transition Therapeutics has commenced a phase I human trial of its interferon enhancing therapy, a therapy that has been demonstrated in preclinical studies to be significantly more effective than interferon alone in the treatment of multiple sclerosis.
Patient dosing in this phase I trial has begun and Transition expects that the trial should be complete by the end of 2002.
Interferon is the current gold standard in the treatment of multiple sclerosis (MS) and is also used for the treatment of hepatitis C, hepatitis B and cancer.
Worldwide sales of interferon are approximately $5.3 billion. Transition previously reported that its interferon enhancing therapy significantly reduced the symptoms and pathologies associated with MS in several different animal models for MS.
Transition has new data showing that this therapy also has more potent
anti-viral and anti-proliferative effects than interferon alone and therefore
may have applications in hepatitis C, hepatitis B and cancer. Transition
plans to perform additional preclinical studies in these areas.
© Copyright 2002, DataMonitor